Consensus Amneal Pharmaceuticals, Inc.

Stocks

AMRX

US03168L1052

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-10-28 EDT			5-day change	1st Jan Change
21.14 ^USD	-1.40%		+6.55%	+67.78%

06:27am	US estrogen supply crunch widens as women seek alternatives to scarce patches	RE
09-23	Amneal Pharmaceuticals' Biosimilars, Specialty Growth Reshape Earnings Profile, Oppenheimer Says	MT

Evolution of the Average Target: Amneal Pharmaceuticals, Inc.

Evolution of the Target Price: Amneal Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Amneal Pharmaceuticals, Inc.

765a0f05c29abbd2.r_gsHKgtH-G8xIvT2pprkrpimJ0Ee8jWfWCkwQJqNBo.-KF5cJBdZ63ovuOSovskq_kV2c19VvyJSSPspUoAcHvpq3t4_15lq4uh6A~ae833db232e187615953c702be6e756e

Analysts' recommendations: Amneal Pharmaceuticals, Inc.

09-23	Amneal Pharmaceuticals' Biosimilars, Specialty Growth Reshape Earnings Profile, Oppenheimer Says	MT
09-23	Oppenheimer Initiates Amneal Pharmaceuticals at Outperform With $27 Price Target	MT
09-09	Leerink Partners Initiates Coverage on Amneal Pharmaceuticals With Outperform, $23 Price Target	MT
08-26	U.S. research roundup- Intuit, MongoDB, Zscaler	RE
08-03	Amneal Pharmaceuticals Has Favorable Setup for Growth With Product Approvals, Launches, UBS Says	MT
08-03	UBS Adjusts Price Target on Amneal Pharmaceuticals to $25 From $23, Maintains Buy Rating	MT
07-15	UBS Adjusts Amneal Pharmaceuticals Price Target to $23 From $19, Maintains Buy Rating	MT
04-17	UBS Initiates Amneal Pharmaceuticals at Buy With $19 Price Target	MT
03-02	Truist Adjusts Price Target on Amneal Pharmaceuticals to $17 From $15, Maintains Buy Rating	MT
01-07	Truist Securities Adjusts Price Target on Amneal Pharmaceuticals to $15 From $14, Maintains Buy Rating	MT
25-10-31	Truist Raises Price Target on Amneal Pharmaceuticals to $14 From $13, Keeps Buy Rating	MT
25-10-30	(AMRX) Amneal Pharmaceuticals Expects Full Year 2025 Adjusted EPS Range $0.75 - $0.80, vs. FactSet Est of $0.76	MT
25-02-24	Amneal Pharmaceuticals' Shares Rise After JPMorgan Upgrade	MT
25-02-24	JPMorgan Upgrades Amneal Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $12 From $9	MT
24-10-02	Truist Raises Price Target on Amneal Pharmaceuticals to $12 From $10, Keeps Buy Rating	MT
24-09-06	JPMorgan Upgrades Amneal Pharmaceuticals to Neutral From Underweight	MT
24-08-12	Truist Adjusts Price Target on Amneal Pharmaceuticals to $10 From $9, Maintains Buy Rating	MT
24-05-06	Goldman Sachs Adjusts Amneal Pharmaceuticals Price Target to $8 From $6.25, Maintains Buy Rating	MT
24-05-03	Truist Securities Raises Amneal Pharmaceuticals' Price Target to $9 From $7, Maintains Buy Rating	MT
24-03-04	Goldman Sachs Adjusts Price Target on Amneal Pharmaceuticals to $6.25 From $5.50, Maintains Buy Rating	MT
24-01-29	Barclays Adjusts Price Target on Amneal Pharmaceuticals to $8 From $6, Maintains Overweight Rating	MT
23-08-07	Truist Adjusts Amneal Pharmaceuticals' Price Target to $6 From $4, Keeps Buy Rating	MT
23-08-07	Barclays Adjusts Price Target on Amneal Pharmaceuticals to $5 From $4, Maintains Overweight Rating	MT
23-05-08	Piper Sandler Adjusts Amneal Pharmaceuticals' Price Target to $3 From $5, Keeps Overweight Rating	MT
23-03-28	Truist Securities Trims Amneal Pharmaceuticals' Price Target to $4 From $5, Maintains Buy Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AMNEAL PHARMACEUTICALS, INC.					+7.28%
	ELI LILLY AND COMPANY					+4.04%
	JOHNSON & JOHNSON					+3.97%
	ABBVIE INC.					-1.12%
	ROCHE HOLDING AG					-3%
	MERCK & CO., INC.					+12.65%
	NOVARTIS AG					-3.77%
	ASTRAZENECA PLC					+23.18%
	AMGEN INC.					-11.3%
	GILEAD SCIENCES, INC.					+0.7%
	Average					+3.26%
	Weighted average by Cap.					+3.07%